clement, Author at BaseLaunch

Expansion of BaseLaunch portfolio of companies 2021

We are proud to announce the recent expansion of our portfolio of companies. We welcome two newcomers - Incephalo and NextImmune - to our family.…

clement23.06.2021

All Portfolio news

Alentis secures $67 Million US dollars

Looking back, what a journey! We remember well when we first started working with Thomas Baumert in late 2017. Built on many years of transformational…

clement21.06.2021

All Features

Swiss Biotech report 2021

Overall, investment in Swiss biotech companies almost tripled on the previous year’s figure. It amounted to 3.44 billion Swiss francs. Investment in research and development…

clement06.05.2021

All Portfolio news

Synendos Therapeutics expands series A to $25 Million

Synendos is developing first-in-class inhibitors. These inhibitors modulate a newly identified drug target in the body’s endocannabinoid system which is a key neuromodulator system in…

clement20.04.2021

Our objective is to enable any player looking to make a difference in healthcare to advance towards their goal...

All Features

A partnership to jumpstart the launch of early-stage startups

In an effort to further grow the flow of innovation centered in the Basel Area, WuXi AppTec and BaseLaunch have joined forces to help young…

clement07.04.2021

Neil Goldsmith Strategic mind at BaseLaunch

All Interviews Team interviews

Featured Interview: Neil Goldsmith, Director Strategy of BaseLaunch

You have been an entrepreneur all your life. How has this experience shaped you and what do you believe BaseLaunch can bring to the table…

clement18.03.2021

All Features

Bifunctional molecules, a diverse new modality

The term "bifunctional molecules" covers a collection of related modalities with different but similar strategies. They are opening up once-inaccessible targets and enabling the development…

clement18.03.2021

Tax relief for biotech startups and non-listed companies

All Features

Tax relief in startups and non-listed companies

Under the current tax framework, the non-uniform cantonal tax practices on the capital gains treatment and valuation of employee shares lead to different tax consequences…

clement18.03.2021

All Features

Biotech companies can also fail

Nowadays, biotech headlines usually talk about hundred million series A financings, oversubscribed IPOs, or multi-billion exits. But success is not guaranteed at all, even when…

clement18.03.2021

Female scientist looking through microscope

All Features

Driving value from genomics in life sciences

In this paper, "Driving value from genomics in life sciences: rising to the data challenge", KPMG explores the cornerstone for genomic data leadership: a robust…

clement18.03.2021

clement

Expansion of BaseLaunch portfolio of companies 2021

Alentis secures $67 Million US dollars

Swiss Biotech report 2021

Synendos Therapeutics expands series A to $25 Million

A partnership to jumpstart the launch of early-stage startups

Featured Interview: Neil Goldsmith, Director Strategy of BaseLaunch

Bifunctional molecules, a diverse new modality

Tax relief in startups and non-listed companies

Biotech companies can also fail

Driving value from genomics in life sciences

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us